I.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia.
N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, 115478, Moscow, Russia.
Viruses. 2020 Feb 4;12(2):173. doi: 10.3390/v12020173.
Oncolytic viruses, including live attenuated measles virus (MV) vaccine strains, have recently been shown as promising therapeutic agents against human malignancies. In this study, the oncolytic potential of the attenuated vaccine strain Leningrad-16 (L-16) of MV was evaluated in a panel of human metastatic melanoma cell lines. The L-16 measles virus was shown to replicate within melanoma cells mediating direct cell killing of tumor cells, although all melanoma cell lines varied in regard to their ability to respond to L-16 MV infection, as revealed by the different pattern of the Interferon Stimulated Gene expression, cytokine release and mechanisms of cell death. Furthermore, the statistically significant L-16 measles virus related tumor growth inhibition was demonstrated in a melanoma xenograft model. Therefore, L-16 MV represents an appealing oncolytic platform for target delivery of therapeutic genes along with other attenuated measles virus strains.
溶瘤病毒，包括减毒麻疹病毒（MV）疫苗株，最近已被证明是对抗人类恶性肿瘤有希望的治疗剂。在这项研究中，评估了减毒疫苗株 Leningrad-16（L-16）MV 在一系列人转移性黑色素瘤细胞系中的溶瘤潜力。L-16 麻疹病毒在黑色素瘤细胞内复制，介导肿瘤细胞的直接细胞杀伤，尽管所有黑色素瘤细胞系对 L-16 MV 感染的反应能力不同，这从干扰素刺激基因表达、细胞因子释放和细胞死亡机制的不同模式中可以看出。此外，在黑色素瘤异种移植模型中，L-16 麻疹病毒相关的肿瘤生长抑制具有统计学意义。因此，L-16 MV 代表了一种有吸引力的溶瘤平台，可用于递呈治疗基因，同时还可使用其他减毒麻疹病毒株。
